(Q40425505)

20 September 2017

title

Fibrinogen and D-dimer levels elevate in advanced hepatocellular carcinoma: High pretreatment fibrinogen levels predict poor outcomes (English)

1 reference

20 September 2017

Zhikun Liu

1

1 reference

20 September 2017

Haijun Guo

2

1 reference

20 September 2017

Feng Gao

3

1 reference

20 September 2017

Qiaonan Shan

4

1 reference

20 September 2017

Jie Li

5

1 reference

20 September 2017

Haiyang Xie

6

1 reference

20 September 2017

Lin Zhou

7

1 reference

20 September 2017

Xiao Xu

8

1 reference

20 September 2017

Shusen Zheng

9

1 reference

20 September 2017

publication date

3 December 2016

1 reference

20 September 2017

1 reference

Promising new strategies for hepatocellular carcinoma

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Hepatocellular carcinoma: clinical frontiers and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Intratumor heterogeneity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Basic mechanisms and pathogenesis of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Anticoagulant modulation of inflammation in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Coagulopathy: its pathophysiology and treatment in the injured patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Serum D-dimer as an indicator of immediate mortality in patients with in-hospital cardiac arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Activation of blood coagulation in cancer: implications for tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

D-dimer antigen: current concepts and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

D-dimer before chemotherapy might predict venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Clinical and prognostic significance of coagulation assays in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

High D-dimer levels are associated with poor prognosis in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Role of tissue factor in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

Cancer and thrombosis: from molecular mechanisms to clinical presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12848

21 January 2018

Identifiers

DOI

10.1111/HEPR.12848

1 reference

20 September 2017

1 reference